What To Expect From Vaxart And Its Quest To Develop COVID-19 Candidate

Apr. 23, 2020 12:18 PM ETVaxart, Inc. (VXRT)15 Comments
Gary Bourgeault profile picture
Gary Bourgeault


  • Vaxart is making progress on its work to develop an oral vaccine to treat COVID-19.
  • We'll look at why its oral delivery vaccine system could differentiate and potentially be superior to many other delivery systems.
  • In the article we'll also consider the probable price range the share price of Vaxart will move in in the months ahead.

vaxart and its near and long term futureSource: company website

Biotech Vaxart (NASDAQ:VXRT) jumped pre-market on April 21 on the news it had achieved positive results in pre-clinical trials concerning work on its oral vaccine candidates for COVID-19.

In this article we'll examine the implications of the progress on the share price of the company going forward, why an oral delivery system could be superior to other vaccine candidates, and what to take into account if considering taking a position in the company.

Before that, we'll look at its most recent earnings report.

Latest earnings

In its last earnings report for the period ended December 31, 2019, the company reported revenue of $3.9 million, more than double the $1.8 million in revenue generated in the same quarter of 2018. Most of that was the result of non-cash sales associated with future royalties.

Royalty revenue from Inavir for the quarter was $2.2 million, up 148 percent year-over-year.

The company had a net loss in the quarter of $6.4 million, up from the $4.9 million loss in the same reporting period of 2018. The bulk of the increase in net loss came from a restructuring charge of $4.9 million in the quarter, which was offset by a drop in research and development expenditure and a boost in revenue. Full-year net loss was $18.6 million, against the loss of $18.3 million in the fourth quarter of 2018. The increase in net loss came from the "absence of a bargain purchase gain of $6.8 million, partially offset by an increase in revenue of $5.7 million."

Full-year revenue came in at $9.9 million, up from the $4.2 million in full-year revenue for 2018. The increase was from an increase in royalty revenue from Inavir in the last calendar quarter of 2019, and recorded revenue in the pre-merger period of January 1-February 13, 2018, of $3.5 million. At the end of 2019

This article was written by

Gary Bourgeault profile picture
I am a former investment advisor and owner of several businesses. These days I invest only for myself while continuing to write on a variety of financial and economic topics.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (15)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.